Published

24 Dec 25

Updated

26 Jun 26

Views

357

Not Invested

HumacyteHUMA

Fair Value

US$2.05

Share price26 Jun

US$0.7265.0% undervalued

1Y-71.04%

7D9.92%

Bioengineered Vascular Tissue Platform Will Transform Trauma And Dialysis Care Over The Coming Years

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

24 Dec 25

Updated

26 Jun 26

Views

357

Not Invested

Shared on 26 Jun 26

Fair value Decreased 74%

HUMA: V012 Dialysis Data Will Shape Future Indication Expansion Prospects

Fresh trial results in dialysis patients suggest Humacyte’s lab-made blood vessel could help people go longer without needing a catheter, giving the company a clearer shot at expanding beyond trauma care. But Wall Street’s view swings sharply as it weighs that progress against funding needs and uncertainty around approval and real-world adoption.

44 views

Fair Value vs Share Price

US$2.05

vs US$0.7265.0% undervalued

402.6%

Revenue growth

0.3%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Humacyte

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential with adequate balance sheet.

Market capUS$193.7m

PB16.7x

Estimated Growth58.1%

Dividend YieldN/A

Full analysis

CEO & management

Laura Niklason

CEO

1.6yrs

CEO Tenure

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.